LVTX is a pharmaceutical company focused on biologicals for advanced prostate carcinoma.
It recently secured a collaboration agreement with Merck to assist in the clinical trials and
the financial burdens it imposes in a quid pro quo related to a share of product margins in the
future. On the 15-minute chart, LVTX burst out of a long-standing consolidation cycle. The
majority of shareholders per Yahoo Finance are insiders and institutions primarily hedge funds.
These people are not clueless. This is a huge money inflow into the market cap. I intend
to follow the money as I see that price has retraced to a good Fibonacci level and with the
last candle may be on a reversal. I know that institutions tend to buy at the VWAP heavily
and as price is below VWAP the impetus is to buy discounted from VWAP. I will follow
the wisdom, experience and expertise of institutional traders. I will go long and assume the
risk of more of a drop with an ATR stop loss. My goal in the trade is to get a 20% gain by the
close on Monday. Getting into an insider trading move is tricky but it is interesting and
can be profitable.